

Table 4.1

**Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Age at Enrollment and Race/Ethnicity for MRC Super Cohort Participants<sup>1</sup> Who Did Not Report a Prevalent Condition at Baseline**

Data as of: March 31, 2018; Events through March 31, 2018

Outcome	Total	Age at Enrollment			
		50-54	55-59	60-69	70-79
<b>Number randomized</b>	44174	6788	9352	19418	8616
<b>Mean follow-up (months)</b>	172.8	183.3	184.3	174.0	149.3
Angina <sup>2</sup>	3236 (0.54%)	399 (0.40%)	580 (0.42%)	1570 (0.59%)	687 (0.70%)
Diabetes (treated)	7618 (1.27%)	1331 (1.34%)	1743 (1.29%)	3437 (1.31%)	1107 (1.10%)
Hysterectomy	1777 (0.49%)	282 (0.51%)	450 (0.52%)	798 (0.49%)	247 (0.41%)
Osteoarthritis <sup>3</sup>	13289 (3.35%)	2281 (2.95%)	3051 (3.10%)	5823 (3.50%)	2134 (3.92%)
Intestinal polyps	10516 (1.78%)	1699 (1.70%)	2475 (1.82%)	4817 (1.85%)	1525 (1.61%)
Lupus	795 (0.13%)	128 (0.12%)	174 (0.12%)	365 (0.13%)	128 (0.12%)
Hypertension treated w/pills	16216 (3.78%)	2635 (3.30%)	3594 (3.48%)	7112 (3.90%)	2875 (4.47%)
COPD <sup>4</sup>	2236 (0.85%)	301 (0.69%)	528 (0.90%)	1111 (0.97%)	296 (0.68%)
Macular degeneration <sup>5</sup>	4486 (1.04%)	354 (0.49%)	735 (0.75%)	2249 (1.18%)	1148 (1.64%)
Alzheimer's disease <sup>5</sup>	3944 (0.91%)	215 (0.30%)	451 (0.46%)	1993 (1.05%)	1285 (1.84%)
Parkinson's disease <sup>5</sup>	560 (0.13%)	54 (0.07%)	103 (0.10%)	298 (0.16%)	105 (0.15%)

Outcomes	Race/Ethnicity					
	American Indian/ Alaskan Native	Asian/Pacific Islander	Black/African American	Hispanic/ Latina	White	Unknown
<b>Number randomized</b>	130	527	14618	6484	22030	385
<b>Mean follow-up (months)</b>	165.6	167.4	158.6	149.9	189.1	173.8
Angina <sup>2</sup>	16 (0.97%)	22 (0.32%)	992 (0.55%)	340 (0.44%)	1832 (0.55%)	34 (0.64%)
Diabetes (treated)	25 (1.56%)	91 (1.32%)	2845 (1.64%)	1110 (1.46%)	3473 (1.04%)	74 (1.43%)
Hysterectomy	4 (0.55%)	12 (0.23%)	411 (0.48%)	267 (0.59%)	1067 (0.48%)	16 (0.46%)
Osteoarthritis <sup>3</sup>	48 (3.92%)	173 (3.28%)	3971 (3.46%)	2011 (3.72%)	6960 (3.20%)	126 (3.45%)
Intestinal polyps	32 (1.92%)	106 (1.61%)	3497 (1.96%)	1290 (1.69%)	5507 (1.71%)	84 (1.65%)
Lupus	3 (0.17%)	6 (0.08%)	287 (0.15%)	131 (0.16%)	364 (0.11%)	4 (0.07%)
Hypertension treated w/pills	58 (4.47%)	189 (3.64%)	4369 (4.46%)	2325 (3.78%)	9142 (3.52%)	133 (3.46%)
COPD <sup>4</sup>	10 (1.44%)	13 (0.40%)	549 (0.63%)	211 (0.53%)	1436 (1.10%)	17 (0.76%)
Macular degeneration <sup>5</sup>	13 (1.01%)	34 (0.71%)	800 (0.57%)	469 (0.75%)	3135 (1.44%)	35 (0.93%)
Alzheimer's disease <sup>5</sup>	11 (0.86%)	36 (0.75%)	967 (0.69%)	408 (0.65%)	2497 (1.14%)	25 (0.66%)
Parkinson's disease <sup>5</sup>	2 (0.16%)	7 (0.15%)	142 (0.10%)	60 (0.10%)	345 (0.16%)	4 (0.11%)

<sup>1</sup> The MRC Super Cohort includes all WHI Hormone Trial participants and all Black/African American and Hispanic/Latina participants from the CT and OS.

<sup>2</sup> During WHI Extension Study 2005-2010, the outcome was angina with hospitalization for a heart condition that may or may not have been related to the angina.

<sup>3</sup> This outcome has not been self-reported on all versions of Form 33 during WHI follow-up. The annualized percentages are corrected for the different amounts of follow-up.

<sup>4</sup> Data only collected during the WHI Extension Study 2010-2020.

<sup>5</sup> Data only collected during the WHI Extension Studies 2005-2020.